News & Events

March 4, 2026

Ablexis Reports 33 AlivaMab® Mouse-Derived Human Antibodies Now in Clinical Development, Further Validating AlivaMab Mouse Transgenic Platform / READ MORE

September 2, 2025

AlivaMab Biologics Announces Milestone- and Royalty-Free Access to AlivaMab® Mouse for Human Antibody Drug Discovery Services / READ MORE

September 2, 2025

Ablexis Announces Validation and Availability of AlivaMab® Mouse-NGX / READ MORE

November 15, 2022

Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities / READ MORE

January 31, 2022

Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development / READ MORE

May 4, 2021

Ablexis Announces Multi-Target License Agreement with Tanabe Research Laboratories U.S.A. / READ MORE

October 16, 2020

Ablexis Announces Further Expansion of Its Intellectual Property on AlivaMab® Mouse and Immunoglobulin Locus Engineering / READ MORE

September 17, 2019

AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen / READ MORE

January 17, 2019

Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company / READ MORE

December 6, 2018

Ablexis Announces Licensing Agreement with Allogene Therapeutics / READ MORE

November 13, 2018

Ablexis Announces Progress in Its Intellectual Property on AlivaMab Mouse and Immunoglobulin Locus Engineering / READ MORE

November 5, 2018

Ablexis Announces Antibody Discovered Using AlivaMab Mouse Platform Enters Clinical Development / READ MORE

October 23, 2018

Ablexis Announces Licensing Agreement with Voyager Therapeutics / READ MORE

October 9, 2018

Ablexis Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center / READ MORE

June 21, 2018

Ablexis Targets Market Expansion Opportunities for AlivaMab Mouse Following Acquisition by Deerfield Management and the Founding of AlivaMab Discovery Services / READ MORE

Ablexis Reports 33 AlivaMab® Mouse-Derived Human Antibodies Now in Clinical Development, Further Validating AlivaMab Mouse Transgenic Platform / READ MORE

AlivaMab Biologics Announces Milestone- and Royalty-Free Access to AlivaMab® Mouse for Human Antibody Drug Discovery Services / READ MORE

Ablexis Announces Validation and Availability of AlivaMab® Mouse-NGX / READ MORE

Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities / READ MORE

Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development / READ MORE

Ablexis Announces Multi-Target License Agreement with Tanabe Research Laboratories U.S.A. / READ MORE

Ablexis Announces Further Expansion of Its Intellectual Property on AlivaMab® Mouse and Immunoglobulin Locus Engineering / READ MORE

AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen / READ MORE

Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company / READ MORE

Ablexis Announces Licensing Agreement with Allogene Therapeutics / READ MORE

Ablexis Announces Progress in Its Intellectual Property on AlivaMab Mouse and Immunoglobulin Locus Engineering / READ MORE

Ablexis Announces Antibody Discovered Using AlivaMab Mouse Platform Enters Clinical Development / READ MORE

Ablexis Announces Licensing Agreement with Voyager Therapeutics / READ MORE

Ablexis Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center / READ MORE

Ablexis Targets Market Expansion Opportunities for AlivaMab Mouse Following Acquisition by Deerfield Management and the Founding of AlivaMab Discovery Services / READ MORE

Conferences

BIO Europe Fall

PEGS Europe

Antibody Engineering and Therapeutics USA

J.P. Morgan Healthcare Conference